Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

Bullboard (TSX:LABS)

View:
Comment by mdjbrownon Apr 06, 2024 12:10pm

RE:RE:Our competition and somewhat good news. MEDIF update us pls.

QC, I am not so sure some of these medical cannabis will be held up as long as traditional FDA medicine approvals, due to its infancy in medicine. Look no further than Epidiolex, which at the time ...more  
Comment by subaru1ion Apr 06, 2024 12:10pm

RE:RE:RE:RE:Our competition and somewhat good news. MEDIF update us pls.

Nicely said mdj.   It should be for all LABS investors at this point based on the information released by the company, it is NOT a matter of if but now only a matter of when and the when ...more  
Comment by mdjbrownon Apr 06, 2024 11:53am

RE:RE:RE:Our competition and somewhat good news. MEDIF update us pls.

Macpoor, if Medipharm shareholders were holding out hope for just one specific outcome, I agree it would be sad, but Labs has so many promising international irons in the fire, one home run will make ...more  
Post by subaru1ion Apr 06, 2024 11:01am

Mdjbrown...Apotex IS a an export doorway to China, NO DOUBT.

1997...therefore already well established in China but keep reading further below.  Apotex, working with LABS could export generic Epidiolex to China and that market dwarfs the U.S. market.  ...more  
Comment by Macpooron Apr 06, 2024 10:44am

RE:RE:Our competition and somewhat good news. MEDIF update us pls.

I agree with you! I believe you make sense with what you said. Taurx pharamcutical a great example with how long it takes to commercialize a new drug. Have they started since 2002 for a drug slowing ...more  
Comment by mdjbrownon Apr 06, 2024 10:41am

RE:RE:A secret pharmaceutical partner

s1i, it is interesting that Avicanna has claimed proprietary SEDDS tech, when it appears there is SEDDS, SMEDDS, and SNEDDS tech used in several delivery system applications?   https:/ ...more  
Comment by mdjbrownon Apr 06, 2024 10:00am

RE:Our competition and somewhat good news. MEDIF update us pls.

Olaf123, if you search LiBBY, Life's End Benefits of Cannabidiol and Tetrahydrocannabinol (LiBBY)  it will provide further information on this trial  https://libbystudy.org/ https ...more  
Comment by subaru1ion Apr 06, 2024 9:24am

RE:A secret pharmaceutical partner

SEDDS used by LABS is a new treatment method because it provides a more efficient form of absorption in the body...wait for the generic Epidiolex launch in the U.S. news from LABS.   We ...more  
Comment by QContinuum1on Apr 06, 2024 9:15am

RE:Our competition and somewhat good news. MEDIF update us pls.

Please keep in mind that while there may well be exciting future drugs based on cannabinoids, the trial you reference is only a Phase II and has a very long way to go before commercialization; quite ...more  
Comment by Olaf123on Apr 06, 2024 4:49am

RE:RE:RE:Our competition and somewhat good news. MEDIF update us pls.

''Last year, Rexulti (brexpiprazole) pulled in 2.85 billion Danish kroner ($405 million) in sales for Lundbeck. In mid-2022, SVB Securities analysts noted that the ...more  
Comment by Olaf123on Apr 06, 2024 4:34am

RE:RE:Our competition and somewhat good news. MEDIF update us pls.

If this study is successful, who will commercialize the drug? '' the Company will supply the Sponsor and the Principal Investigators with the study drug and placebo, and such other ...more  
Comment by Olaf123on Apr 06, 2024 4:22am

RE:Our competition and somewhat good news. MEDIF update us pls.

For more context: https://www.newswire.ca/news-releases/medipharm-labs-enters-cannabis-research-agreement-with-keck-school-of-medicine-of-usc-865838274.html
Post by Solid1on Apr 06, 2024 4:21am

A secret pharmaceutical partner

As far as the generic of Epidiolex is concerned, I think it's more about the active ingredients in this drug... The GW/Jazz patents relate to the treatment of epilepsy. If the pharma partner has ...more  
Post by Olaf123on Apr 06, 2024 4:02am

Our competition and somewhat good news. MEDIF update us pls.

IGC pharma is developing like us a drug for Alzheimer agitation disorder https://youtu.be/op8VMy43rFQ?si=y3SHC5hVLhTjSlBt&t=74 They said this is the first natural cannabis ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities